Amphista Therapeutics

SVP, Chemistry Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. Amphista is a leader in next generation targeted protein degradation (TPD) approaches and is currently applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the [...]

By |11 September 2023|Categories: |Tags: |0 Comments

Closed Loop Medicine

Non-Executive Director Closed Loop Medicine is a TechBio company developing combination prescription drug plus software products, with the aim of redefining precision medicine. The Company’s proprietary technology platform facilitates personalised drug dosing optimisation, through integration of drugs and software with patient-led digital experiences and closed loop models of care. This approach has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Founded at the Babraham Institute in Cambridge, UK in 2017, and now based in London, UK, Closed Loop Medicine (CLM) has to date raised over £22 million GBP ($30 million USD) in [...]

By |28 July 2022|Categories: |Tags: |0 Comments

Owlstone Medical

Non-Executive Director Owlstone Medical Ltd is an award-winning and innovative growth stage global diagnostics organisation pioneering the development of a breathalyzer for applications in early disease detection and precision medicine. Founded in 2014, as a spin out of the successful Owlstone Inc. business, Owlstone Medical has a mission to save over 100,000 lives through the deployment of its clinical stage Breath Biopsy® platform for early disease detection and precision medicine. In 2021, following impressive growth, with over 170 employees and having raised almost $100m in investment, Owlstone Medical’s Board of Directors determined a strategic business need to appoint an internationally [...]

By |24 January 2022|Categories: |Tags: |0 Comments


Chief Business Officer Head of LifeArc Ventures LifeArc is a leading independent medical research charity that rebranded since its formation as the MRC-T over 25 years ago. LifeArc’s expertise has helped bring a number of new innovations to market including major commercialised antibody treatments such as Keytruda® (pembrolizumab). The success of Keytruda® has resulted in the receipt of nearly £1billion for monetising a portion of its royalty rights, funds which LifeArc have sought to effectively deploy to increase the impact that they deliver. As LifeArc undergoes transformative change, Melanie Lee, CEO, sought to appoint several experienced executives from the life [...]

By |23 September 2020|Categories: |Tags: |0 Comments

Futura Medical

Non-Executive Directors Futura Medical PLC (“Futura” or the “Company”) is an AIM listed pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain. In 2021, Futura received EU regulatory approval for its breakthrough, fast acting topical gel formulation for the treatment of erectile dysfunction (“ED”) and is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction known as MED3000 (Eroxon™). In addition, the remaining clinical study that the Company believes is required in order to submit MED3000 for US [...]

By |13 January 2022|Categories: |Tags: |0 Comments


Non-Executive Finance Trustee LifeArc is a leading independent medical research charity that rebranded since its formation as the MRC-T over 25 years ago. LifeArc’s expertise has helped bring a number of new innovations to market including major commercialised antibody treatments such as Keytruda® (pembrolizumab). As an independent charity, LifeArc is guided and governed by a Board of Trustees comprised of leading figures from the Pharmaceutical, Biotech, Charitable and Investment sector. As part of a strategic relationship, PIR International partnered with LifeArc to appoint a new Non-Executive Finance Trustee to its board. As a result of a thorough search exercise, drawing [...]

By |01 September 2020|Categories: |Tags: |0 Comments


Chief Executive Officer Chief Commercial Officer Congenica is a digital health company enabling genomic medicine with the world’s leading clinical decision support platform for accelerated genomic data interpretation. Congenica are committed to integrating clinical genomics into healthcare. Built on a foundation of clinical genomics expertise, they develop software products and services that make the use of complex genomic data routine, accessible and ubiquitous. This innovative venture-capital backed growth stage business engaged Stuart Penney and Tom Bradley to build-out their executive team to scale the business as it commercialised internationally. As a result of an extensive global search exercise, both David [...]

By |28 June 2019|Categories: |Tags: |0 Comments


Chief Scientific Officer Chief Medical Officer Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies targeting a broad range of solid cancers with a high unmet medical need. In November 2017 Zelluna announced the appointment of Miguel Forte as Chief Executive Officer.  One of Miguel’s key objectives is to lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities. To assist Miguel in driving the business forward he [...]

By |28 June 2019|Categories: |Tags: |0 Comments

NMD Pharma

Chief Medical Officer Chief Development Officer SVP Regulatory Affairs VP Clinical Operations NMD Pharma is a promising Danish biotechnology company dedicated to the development of a paradigm, innovative and life-changing treatment for patients with reduced muscle function due to compromised neuromuscular transmission as experienced in Myasthenia Gravis and other rare neuromuscular disorders. Following an impressive Series A funding round, backed by major venture capital players, the NMD Pharma Founders and Board engaged Tom Bradley and Stuart Penney to undertake two key searches for a Chief Medical Officer and Chief Development Officer to compliment the advancement of NMD Pharma key programmes [...]

By |28 June 2019|Categories: |Tags: |0 Comments
Go to Top